This review outlines the assessment of direct oral anticoagulants, their antidotes, and the management of bleeding and stroke complications in patients with non-valvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May inform DOAC bleeding management in AF; leaves open prospective validation of reversal protocols.
Oral anticoagulation is mandatory for patients at high risk of thromboembolism, but the risk of bleeding should also be taken into account. Direct oral anticoagulants are now recommended for non-valvular AF as a potential alternative to warfarin. In this article we discuss methods to assess the anticoagulant effect of these agents, specific and general antidotes, and management of complications such as embolic and haemorrhagic stroke, and significant bleeding.
No takes yet. Share an insight, caveat, or question.
Katritsis et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: